Pfizer INC Form 4 insider transactions

Executive Vice President of Pfizer, Douglas M. Lankler, reports acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the acquisition of restricted stock units and stock appreciation rights.

Executive Vice President Alexandre de Germay reports acquisition of Pfizer stock and stock appreciation rights on February 27, 2024.

Executive Vice President Michael McDermott reports the earn-out of stock appreciation rights and withholding of shares for tax obligations and exercise price payments.

Sally Susman, Executive Vice President of Pfizer, reports the earn-out of stock appreciation rights and related transactions on February 23, 2024.

Executive Vice President Payal Sahni reports the earn-out of stock appreciation rights and related transactions, including share withholding for tax obligations and exercise price payments.

Executive Vice President Douglas M. Lankler reports the earn-out and subsequent transactions of stock appreciation rights, including share withholding for tax obligations and exercise price, affecting his beneficial ownership of Pfizer common stock.

Executive Vice President Rady A. Johnson reports the earn-out of stock appreciation rights and related transactions involving Pfizer Inc. common stock.

Mikael Dolsten, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon settlement of stock units.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the earn-out of stock appreciation rights and withholding of shares to cover tax obligations and exercise price.

Pfizer's CEO, Albert Bourla, exercised stock appreciation rights and adjusted his holdings of Pfizer common stock on February 23, 2024.

Executive Vice President Christoffel Boshoff reports multiple transactions involving Pfizer Inc. (PFE) common stock, including the exercise of stock appreciation rights and vesting of performance share awards.